Version history

{
  "session_id": "sess_SDA-2026-04-14-gap-pubmed-20260410-185318-186b0446",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Critical Evaluation of Genetic Risk Factor Hypotheses for CTE\n\nI'll systematically evaluate each hypothesis, identifying specific weaknesses, counter-evidence with real PubMed citations, alternative explanations, and falsification experiments.\n\n---\n\n## Hypothesis 1: TREM2 R47H Variant\n\n### Specific Weaknesses in Evidence\n\n**1. Evidence Domain Mismatch:** The cited PMIDs (23571350, 23883924) derive almost exclusively from Alzheimer's disease amyloid models. TREM2's protective effect in AD operates through enhanced microglial clustering around amyloid plaques—a pathology with a fundamentally different seeding mechanism than CTE's trauma-induced tauopathy. The assumption that the same mechanism applies to tau aggregate clearance lacks validation.\n\n**2. Population Frequency Problem:** TREM2 R47H has an allele frequency of approximately 0.3-0.5% in European populations. Given the estimated prevalence of CTE-related pathology in contact sport athletes (potentially 20-30% in professional football players), this variant cannot account for anything but a tiny fraction of cases. Genetic risk factors with population frequencies <1% cannot explain the observed epidemic-level disease burden.\n\n**3. Mechanistic Speculation:** The hypothesis assumes tau aggregates are cleared by the same TREM2-dependent phagocytic pathway as amyloid plaques. However, tau aggregates are intracellular and propagate via trans-synaptic spread, whereas amyloid plaques are extracellular deposits. Microglial phagocytosis of extracellular debris may be mechanistically irrelevant to intracellular tau pathology.\n\n### Counter-Evidence\n\n**4. Differential Effect in Tauopathies vs. Amyloidoses:** Multiple GWAS studies show TREM2 variants have opposite effects depending on whether individuals have amyloid pathology. In pure tauopathies without amyloid, TREM2 risk variants may have neutral or even protective effects.\n\n**5. Lack of CTE-Specific Association:** No published study has demonstrated an association between TREM2 variants and CTE risk, staging, or progression. The cited CTE post-mortem study (PMID: 25904048) describes microglial morphology but does not genotype TREM2 variants or correlate with genotype.\n\n**6. TREM2 Expression Pattern:** TREM2 expression in CTE-relevant brain regions (brainstem, diencephalon) may be lower than in cortical regions where AD pathology predominates, potentially limiting the variant's biological impact in CTE.\n\n### Alternative Explanations\n\n- **Other TREM2 Common Variants:** Other TREM2 SNPs with higher population frequencies (but smaller effect sizes) may contribute to CTE risk through additive or multiplicative effects with trauma exposure.\n- **Non-Genetic Microglial Dysfunction:** Repetitive brain trauma itself causes microglial activation and dysfunction independent of TREM2 genotype, through damage-associated molecular pattern (DAMP) release.\n- **Timing of Assessment:** TREM2-mediated microglial responses may be protective acutely but pathogenic chronically—the net effect depends on when risk is assessed.\n\n### Key Experiments to Falsify\n\n1. **Genotype-stratified CTE GWAS:** Perform genome-wide association analysis specifically in CTE cases vs. trauma-exposed controls, looking for TREM2 signals with adequate power (>5,000 cases).\n2. **iPSC Microglial Models:** Generate microglia from TREM2 R47H carriers and non-carriers, expose to CTE-relevant stimuli (repetitive mechanical strain, tau oligomers), and quantify phagocytic clearance of tau species.\n3. **Animal Model Requirement:** Cross TREM2 R47H knock-in mice with repetitive trauma models to demonstrate accelerated tau pathology *specifically* attributable to the variant—not merely recapitulating trauma effects.\n\n### Revised Confidence Score: **0.38**\n\n---\n\n## Hypothesis 2: GRN Haploinsufficiency\n\n### Specific Weaknesses in Evidence\n\n**1. GRN Mutations Cause a Distinct Disease, Not a Risk Factor:** Granulins are not merely \"risk modifiers\" for CTE—they cause autosomal dominant frontotemporal dementia (FTD-GRN) with onset typically before age 65. The neuropathology (TDP-43 type A inclusions) overlaps only partially with CTE's signature pathology. Conflating a monogenic cause of dementia with a risk modifier for trauma-induced disease is conceptually problematic.\n\n**2. The \"Haploinsufficiency Threshold\" Problem:** Individuals with GRN mutations (~50% protein levels) develop FTD with high penetrance regardless of trauma exposure. If haploinsufficiency were truly the mechanism, we would predict CTE-like disease in all GRN mutation carriers—yet the clinical phenotype is distinct from typical CTE, and CTE pathology has not been systematically assessed in GRN mutation carriers.\n\n**3. TDP-43 Pathology Does Not Equate to CTE:** The claim that \"TDP-43 pathology observed in >80% of CTE cases\" (PMID: 25904048) supports TDP-43 involvement but does not establish that GRN-mediated lysosomal dysfunction drives this pathology. TDP-43 mislocalization in CTE may occur through trauma-triggered pathways entirely independent of progranulin biology.\n\n### Counter-Evidence\n\n**4. GRN Mutations Are Not Enriched in CTE Populations:** No study has reported increased GRN mutation frequency or progranulin levels in CTE cases compared to appropriate controls.\n\n**5. Counter-Regulatory Mechanisms:** Haploinsufficient states often trigger compensatory upregulation of remaining wild-type allele or related proteins (e.g., progranulin analogs). The lysosomal dysfunction phenotype is established in overexpression systems and may not fully manifest with the subtle changes relevant to sporadic CTE.\n\n**6. Mechanistic Disconnect:** The link between GRN haploinsufficiency and TDP-43 pathology is itself debated. Mouse models of Grn haploinsufficiency show lysosomal dysfunction but inconsistent TDP-43 pathology, and TDP-43 inclusions in GRN-FTD may require additional aging-related or stochastic events.\n\n### Alternative Explanations\n\n- **Triggered TDP-43 Mislocalization:** Trauma itself may cause TDP-43 pathology through a GRN-independent mechanism (impaired axonal transport, cytoskeletal disruption), and GRN variants may simply modulate resilience without being determinative.\n- **Shared Vulnerability Pathway:** Both GRN haploinsufficiency and repetitive trauma may converge on the same cellular pathway (lysosomal stress, impaired autophagy), but this convergence may not represent a genetic risk factor in the conventional sense.\n\n### Key Experiments to Falsify\n\n1. **Rare Variant Burden Analysis:** Sequence GRN in large CTE cohorts (>1,000 cases) and compare rare variant burden to matched controls. If GRN variants confer risk, we expect enrichment of potentially damaging variants.\n2. **Progranulin Levels in CTE:** Measure progranulin levels in CSF or plasma from CTE cases and correlate with GRN genotypes and TDP-43 pathology status. Risk alleles should associate with lower progranulin and higher TDP-43 pathology.\n3. **Trauma Response in GRN haploinsufficient mice:** Subject Grn+/- mice to controlled cortical impact or closed-head impact models and assess TDP-43 pathology at various timepoints vs. wild-type littermates.\n\n### Revised Confidence Score: **0.29**\n\n---\n\n## Hypothesis 3: MAPT H1/H2 Haplotype\n\n### Specific Weaknesses in Evidence\n\n**1. Non-Peer-Reviewed Evidence:** The \"ENIGMA consortium\" citation is explicitly marked as \"computational\" without a PMID, suggesting unpublished data. Scientific hypotheses require peer-reviewed evidence. The confidence should not rest on unpublished analyses.\n\n**2. CTE Has a Distinct Tauopathy from PSP/CBD:** While MAPT H1 is associated with increased risk for progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), these are 4-repeat tauopathies with different anatomical distributions and pathological signatures than CTE (which involves both 3-repeat and 4-repeat tau, with characteristic perivascular and deep brain involvement). The assumption that genetic risk factors for PSP transfer to CTE risk is unsupported.\n\n**3. Population Prevalence Problem:** The MAPT H1 haplotype occurs in approximately 70-75% of European populations. If H1/H1 homozygosity substantially increased CTE risk, we would expect nearly ubiquitous disease in contact sport athletes—yet CTE prevalence remains substantially less than 100%, suggesting either incomplete penetrance or that H1 status is a weak modifier rather than a major risk determinant.\n\n### Counter-Evidence\n\n**4. MAPT H1 Paradox in Alzheimer's Disease:** Despite increasing tau expression, MAPT H1 haplotype is *protective* for Alzheimer's disease risk, contrary to what would be predicted if simply \"more tau = more disease.\" This demonstrates that the relationship between tau expression levels and neurodegeneration is complex and context-dependent.\n\n**5. Negative or Mixed Association Studies:** Some studies in traumatic brain injury populations have failed to find robust associations between MAPT haplotypes and outcomes, suggesting the effect may be context-specific or modest.\n\n**6. CTE Staging Does Not Correlate with MAPT:** The characteristic progressive staging pattern of CTE (Stage I-IV) shows stronger correlation with trauma exposure duration and intensity than with any known MAPT variant.\n\n### Alternative Explanations\n\n- **Gene-Environment Interaction Specificity:** MAPT H1 may modify the relationship between trauma and tau pathology only under specific conditions (e.g., certain ages of exposure, specific trauma types) that have not been adequately characterized.\n- **Linkage Disequilibrium:** MAPT H1 is in linkage disequilibrium with other nearby variants (e.g., in the RCAN1, KCNIP4 genes) that may actually drive the association. The causal variant has not been definitively identified.\n\n### Key Experiments to Falsify\n\n1. **Prospective Genotype-Phenotype Study:** Genotype MAPT in well-characterized athlete cohorts with longitudinal follow-up, with standardized concussion counts and neuroimaging (tau PET). If H1/H1 carriers show accelerated tau PET signal over time, the hypothesis is supported.\n2. **Post-mortem Correlation:** Assess MAPT haplotype in CTE cases and correlate with NFT distribution, burden, and composition (3R vs. 4R tau). If H1 drives enhanced tau propagation, we predict more severe and widespread pathology.\n3. **Mendelian Randomization:** Use MAPT haplotype as an instrumental variable to test whether genetically predicted higher tau expression causally increases CTE risk, avoiding confounding.\n\n### Revised Confidence Score: **0.44**\n\n---\n\n## Hypothesis 4: BDNF Val66Met Polymorphism\n\n### Specific Weaknesses in Evidence\n\n**1. Protective Factor Confusion:** The hypothesis frames BDNF Val66Met as increasing vulnerability, but BDNF signaling is also required for pathological processes. Increased neuronal activity-dependent BDNF release in Val/Val individuals may actually increase excitotoxicity following trauma, potentially conferring *greater* vulnerability to seizure and hypermetabolic states.\n\n**2. Interaction vs. Main Effect:** The cited evidence demonstrates that Met carriers have reduced hippocampal volume and memory performance (PMID: 15122978), but these effects may be independent of, or interact differently with, trauma exposure than assumed. A genetic main effect on cognition does not automatically translate to an interaction with brain trauma.\n\n**3. The \"Exercise Compensates\" Complication:** If exercise is an effective intervention for CTE—and BDNF elevation is a key mechanism—then the polymorphism creates a paradox: Met carriers benefit less from exercise, but also may need it more. This makes therapeutic translation complex.\n\n### Counter-Evidence\n\n**4. Inconsistent TBI Associations:** Studies specifically examining BDNF Val66Met in TBI populations have yielded inconsistent results. Some report worse outcomes in Met carriers; others find no association or even protective effects in specific contexts.\n\n**5. Met Carriers May Have Neuroprotective Trade-offs:** Reduced activity-dependent BDNF secretion may paradoxically protect against excitotoxic damage during acute trauma, as the burst of excitatory neurotransmitter release that occurs during TBI would drive less BDNF secretion in Met carriers—potentially reducing downstream pro-apoptotic signaling.\n\n**6. Effect Size Considerations:** The functional effect (30% reduction in activity-dependent secretion; PMID: 12537919) is modest, and in the complex polygenic context of CTE risk, this may represent a small contributor that is difficult to detect against the noise of environmental factors.\n\n### Alternative Explanations\n\n- **Endophenotype Modifier:** BDNF Val66Met may not modify CTE risk per se, but rather modify which symptoms predominate (cognitive vs. behavioral/mood), creating clinical heterogeneity rather than altering underlying neuropathology.\n- **Epigenetic Compensation:** Long-term activity patterns and environmental enrichment may compensate for Met genotype through epigenetic upregulation of BDNF or TrkB receptor signaling.\n\n### Key Experiments to Falsify\n\n1. **Longitudinal Genotype-Phenotype Study:** Track Met and Val carriers exposed to repetitive brain trauma longitudinally with cognitive testing and biomarkers. If the hypothesis holds, Met carriers should show accelerated decline—but the study must control for pre-injury baseline cognitive function.\n2. **BDNF Response to Concussion:** Measure acute BDNF response to concussion in Met vs. Val carriers and correlate with post-concussion symptom duration and severity. Failure to find genotype-dependent differences would falsify the acute mechanism.\n3. **Intervention by Genotype:** If a BDNF mimetic therapy is trialed in CTE, compare efficacy in Met vs. Val carriers. If the therapy works equally well in both groups, the polymorphism's functional significance is questioned.\n\n### Revised Confidence Score: **0.52**\n\n---\n\n## Hypothesis 5: P2RX7 Gain-of-Function Variants\n\n### Specific Weaknesses in Evidence\n\n**1. Variant Rarity and Effect Specificity:** The cited P2RX7 variants (Q460R, A348T) are uncommon in the general population. More importantly, these variants were identified in inflammatory disease cohorts, and their functional effects on neuroinflammatory signaling specifically are less well-characterized than implied.\n\n**2. Animal Model Limitations:** The evidence that P2X7 receptor blockade reduces neuroinflammation after TBI (PMID: 26711532) is from animal models, where drug dosing and receptor specificity may not translate to human disease. Additionally, the therapeutic window and chronic dosing requirements for CTE prophylaxis are not established.\n\n**3. Inflammasome as Secondary Phenomenon:** Chronic NLRP3 inflammasome activation may be a secondary response to neurodegeneration rather than a primary driver. If inflammation is downstream of tau pathology, targeting P2RX7 would not prevent disease initiation.\n\n### Counter-Evidence\n\n**4. P2RX7 Null Mutations and Compensation:** Complete loss-of-function P2RX7 mutations in humans and mice do not cause catastrophic immune dysfunction, suggesting redundant pathways. Gain-of-function variants may similarly be compensated by other purinergic receptors or inflammasome components.\n\n**5. Divergent Effects in Acute vs. Chronic Settings:** P2RX7-mediated microglial activation is neuroprotective in acute injury (clearing debris, responding to infection), while chronic activation drives pathology. The same genetic variant would need to create a specific shift in temporal dynamics to preferentially cause CTE—mechanistically unlikely.\n\n**6. CSF IL-1β Not Elevated in CTE:** If chronic NLRP3 activation drove CTE, we would expect persistently elevated IL-1β in CSF. Published CTE biomarker studies show variable results without the consistent elevation pattern predicted by the hypothesis.\n\n### Alternative Explanations\n\n- **Trigger Threshold Model:** All individuals with sufficient trauma exposure develop chronic inflammation; genetic variants merely determine the threshold of trauma required to cross the pathological threshold.\n- **Microglial Polarization State:** P2RX7 may influence M1/M2 microglial polarization balance rather than overall activation state, with different implications for neurodegeneration depending on context.\n\n### Key Experiments to Falsify\n\n1. **P2RX7 Genotype in CTE Cases:** Sequence P2RX7 in a large CTE cohort and controls, looking for enrichment of known gain-of-function variants. No published study has performed this analysis.\n2. **Inflammatory Biomarker Profiling:** Correlate P2RX7 genotype with CSF/plasma inflammatory markers (IL-1β, IL-18, NLRP3 activity) in CTE cases vs. controls. If variants don't predict inflammatory state, the mechanism is discredited.\n3. **Prospective Trauma Response Study:** Genotype contact sport athletes before injury, then track inflammatory biomarker trajectories following concussions. If P2RX7 genotype predicts recovery kinetics, this would support the hypothesis—but published data are lacking.\n\n### Revised Confidence Score: **0.31**\n\n---\n\n## Hypothesis 6: SORL1 Variants\n\n### Specific Weaknesses in Evidence\n\n**1. Primary Amyloid Hypothesis Problem:** CTE amyloid deposition occurs in only a subset of cases (older athletes), while the pathognomonic feature is tauopathy. SORL1's mechanism involves APP trafficking and amyloid processing, which is irrelevant to the majority of CTE cases where amyloid is absent. The hypothesis can only explain CTE progression in amyloid-positive individuals.\n\n**2. Mechanistic Disconnect:** Even if SORL1 variants increase amyloid deposition after trauma (PMID: 16878169), the evidence that amyloid then \"creates a nidus for subsequent tau pathology\" is not established. Amyloid and tau pathologies in CTE may be independent processes that happen to co-occur in some individuals.\n\n**3. Effect Size in AD is Modest:** SORL1 variants identified in AD GWAS have modest effect sizes (OR 1.1-1.3). Given the substantial environmental contribution from repetitive trauma, the expected attributable risk from SORL1 variants in CTE would be even smaller.\n\n### Counter-Evidence\n\n**4. Amyloid Deposition Pattern in CTE:** In CTE cases where amyloid is present, it tends to be diffuse rather than neuritic, and its anatomical distribution differs from AD. This suggests a different biogenesis pathway that may not be SORL1-dependent.\n\n**5. SORL1 Expression is Activity-Dependent:** The claim that \"SORL1 expression is activity-dependent\" (PMID: 29030435) actually suggests that repetitive brain trauma would alter SORL1 expression independent of genotype, potentially compensating for any variant effect.\n\n**6. Negative Results in Some Cohorts:** Some studies of SORL1 variants in TBI populations have not found robust associations with outcomes, suggesting the effect may be specific to AD or other amyloid-prone conditions.\n\n### Alternative Explanations\n\n- **Amyloid-Independent Tau Initiation:** Tau pathology in CTE initiates through trauma-induced axonal injury and phosphorylation cascades that are entirely independent of amyloid, making SORL1 irrelevant for most cases.\n- **Age as Confound:** The association between SORL1 variants and CTE outcomes may be confounded by the fact that amyloid-positive CTE is more common in older individuals, who also have more cumulative exposure and different genetic backgrounds.\n\n### Key Experiments to Falsify\n\n1. **SORL1 Genotype and Amyloid PET:** Assess whether SORL1 variant carriers show differential amyloid PET signal following repetitive brain trauma, specifically separating amyloid-positive from amyloid-negative CTE cases.\n2. **SORL1 and Tau PET:** If SORL1's effect is on tau pathology specifically (through indirect mechanisms), SORL1 genotype should predict tau PET signal independent of amyloid status—this has not been demonstrated.\n3. **Mechanistic Rescue Studies:** Demonstrate that SORL1 overexpression or gene therapy prevents amyloid deposition and accelerates tau pathology in a trauma model; failure to find this would falsify the \"nidus\" hypothesis.\n\n### Revised Confidence Score: **0.28**\n\n---\n\n## Hypothesis 7: CLU C Allele\n\n### Specific Weaknesses in Evidence\n\n**1. Effect Size Too Small for CTE:** The cited OR for CLU C allele in AD is approximately 1.16 (PMID: 18817531)—one of the smallest effect sizes among AD risk genes. In a disease where environmental factors (trauma exposure) explain substantial variance, a genetic variant with OR 1.16 would contribute minimally to overall risk.\n\n**2. The Protective Variant Paradox:** The minor allele at rs11136000 (T) is protective for AD, while the major C allele confers risk. This means 70-80% of individuals carry the \"risk\" allele—yet CTE does not affect the majority of contact sport athletes, again highlighting the inconsistency between population allele frequency and disease prevalence.\n\n**3. Elevated CLU May Be Reactive, Not Causal:** The finding that \"elevated clusterin levels in CSF of CTE patients correlate with disease severity\" (PMID: 29881572) is equally consistent with clusterin being a compensatory protective response to neurodegeneration rather than a driver of pathology.\n\n### Counter-Evidence\n\n**4. CLU's Chaperone Function is Broad:** CLU binds multiple misfolded proteins and lipids, not just tau. Its functional effects are pleiotropic, and impaired chaperone function would manifest in many contexts that are not CTE-specific.\n\n**5. Null CLU Models Don't Recapitulate CTE:** Clusterin knockout mice do not develop spontaneous neurodegeneration, and their response to various stresses shows complex, context-dependent outcomes without the specific tauopathy signature of CTE.\n\n**6. CLU Variant Function is Poorly Understood:** The causal variant at the CLU locus has not been definitively identified. The SNP used as a marker (rs11136000) is likely in linkage disequilibrium with the true causal variant, introducing uncertainty about which gene or regulatory element is actually responsible.\n\n### Alternative Explanations\n\n- **Biomarker vs. Risk Factor:** CLU levels may serve as a biomarker of ongoing neurodegeneration without contributing causally to disease progression. In this model, genetic variants would not predict CTE risk but rather disease severity once established.\n- **Interaction with Other Genetic Networks:** CLU may function within a protein network where compensatory upregulation by other chaperones (e.g., Hsp70 family) dilutes the functional impact of the C allele.\n\n### Key Experiments to Falsify\n\n1. **CLU C Allele and Chaperone Activity:** Directly measure chaperone activity of CLU isolated from C/C vs. T/T individuals. If activity does not differ, the mechanistic premise is false.\n2. **Longitudinal CLU Level Trajectories:** Track whether CLU levels rise before or after tau pathology becomes detectable. If CLU elevation follows tau accumulation, it suggests a secondary response rather than a driving risk factor.\n3. **CLU Genotype in CTE Cases:** The absence of CTE-specific CLU genotype studies is itself a major weakness. Until such studies are published, the hypothesis remains highly speculative.\n\n### Revised Confidence Score: **0.24**\n\n---\n\n## Summary: Revised Confidence Scores\n\n| Hypothesis | Original Score | Revised Score | Primary Issue |\n|------------|---------------|---------------|---------------|\n| 1: TREM2 R47H | 0.72 | **0.38** | Evidence from AD models; variant too rare |\n| 2: GRN Haploinsufficiency | 0.65 | **0.29** | Causes FTD, not CTE risk factor |\n| 3: MAPT H1/H2 | 0.70 | **0.44** | Unpublished data; wrong tauopathy model |\n| 4: BDNF Val66Met | 0.78 | **0.52** | Mixed TBI evidence; effect size modest |\n| 5: P2RX7 | 0.61 | **0.31** | Variant rarity; animal model limitations |\n| 6: SORL1 | 0.58 | **0.28** | Amyloid-centric; irrelevant to tauopathy |\n| 7: CLU | 0.55 | **0.24** | Effect size too small; biomarker confusion |\n\n---\n\n## Meta-Analysis: Cross-Cutting Weaknesses\n\n**1. Missing Direct CTE Evidence:** Across all seven hypotheses, the majority of cited PMIDs derive from Alzheimer's disease, Parkinson's disease, FTD, or general TBI studies—not specifically from CTE populations. This represents a fundamental evidence gap.\n\n**2. Population Prevalence Paradox:** For any common genetic variant to explain a substantial fraction of CTE risk, it should have: (a) substantial effect size, and (b) population frequency consistent with CTE prevalence (~20-30% of exposed athletes). Most cited variants fail both criteria.\n\n**3. Mechanistic Transfer Problem:** Each hypothesis assumes that because a gene is implicated in one neurodegenerative disease, it must operate through the same mechanism in CTE. CTE's unique features (perivascular tau predilection, mixed 3R/4R tau, trauma-triggered onset) may not share mechanistic pathways with other proteinopathies.\n\n**4. Absence of CTE GWAS:** There are no published genome-wide association studies specifically for CTE. Until such studies are performed with adequate sample sizes (>1,000 cases), genetic hypotheses for CTE remain conjectural.\n\n**5. The Polygenic Risk Score Premise is Premature:** The summary's suggestion that \"multi-gene polygenic risk scores\" could enable precision risk stratification is premature. A PRS requires: (a) genome-wide significant hits, (b) calibrated effect sizes, and (c) validation in independent cohorts. None of these conditions are met for CTE.\n\n---\n\n## Recommended Priority Research\n\n1. **CTE GWAS with >3,000 cases** to identify robust genetic signals before building polygenic models\n2. **APOE ε4 stratification** (acknowledged as highest-confidence) should be the priority mechanism for investigation\n3. **Gene-environment interaction studies** recognizing that genetic risk factors for CTE may only manifest in the context of sufficient trauma exposure\n4. **Post-mortem genotype correlation studies** associating known genotypes with CTE neuropathological staging and burden",
  "tokens_used": "6486",
  "persona_id": "persona-skeptic"
}